What distinguishes Section 361 HCT/Ps from Section 351 biological drugs?

Section 361 HCT/Ps are regulated solely under the Public Health Service Act and do not require pre-market FDA approval, provided they meet strict criteria: minimal manipulation, homologous use, no systemic effect, and no added drugs or devices. Section 351 products fail one or more of these criteria and are regulated as drugs, biological products, or medical devices requiring full IND or BLA pre-market approval.

What documentation must a distributor provide before a clinic purchases tissue products?

A compliant distributor or processor must provide proof of FDA Establishment Registration (Form FDA 3356), relevant state tissue bank licenses, third-party accreditation (such as AATB), and lot-specific Certificates of Analysis (CoAs) verifying sterility, endotoxin levels, and negative donor infectious disease screening.

How does minimal manipulation apply to structural versus non-structural human tissues?

For structural tissue (such as bone, skin, or amniotic membrane), minimal manipulation means processing does not alter the original structural characteristics relevant to reconstruction, repair, or support. For non-structural tissue (such as cellular blood components), minimal manipulation means processing does not alter the relevant biological characteristics.

Who is legally responsible if a practice administers a non-compliant tissue product?

Both the tissue manufacturer and the administering clinical practice bear regulatory and legal responsibility. Administering an unapproved Section 351 drug marketed improperly as a Section 361 product exposes a clinical practice to FDA warning letters, regulatory enforcement, professional licensure actions, and potential malpractice exposure.

What cold-chain tracking is required for cryogenic tissue shipments?

Tissue shipments requiring frozen or cryogenic storage must include continuous temperature logging devices or validated temperature indicators within the packaging. Clinics receiving these shipments must verify and document acceptable transit temperatures upon arrival before moving items into practice storage units.

Section 361 Human Cellular Products Procurement Checklist

A Section 361 human cellular products procurement checklist enables healthcare compliance officers to systematically evaluate vendor registration, homologous use definitions, minimal manipulation standards, and chain-of-custody documentation under FDA 21 CFR Part 1271. Establishing rigorous vetting protocols ensures practices acquire compliant human cells, tissues, and cellular and tissue-based products (HCT/Ps) while mitigating clinical risk and regulatory enforcement exposure.

Navigating the procurement of human cells, tissues, and cellular and tissue-based products requires compliance officers and practice administrators to maintain strict oversight. The regulatory boundary dividing Section 361 HCT/Ps from Section 351 biological drugs dictates how these materials are manufactured, labeled, marketed, and administered. For medical directors and procurement managers overseeing [/who-we-serve/pain-management-doctors](pain management practices), orthopedic clinics, or regenerative medicine centers, establishing an enterprise-level compliance framework is essential.

Regulatory Foundations: 21 CFR Part 1271

Under Title 21 of the Code of Federal Regulations (CFR) Part 1271, the U.S. Food and Drug Administration (FDA) regulates HCT/Ps intended for implantation, transplantation, infusion, or transfer into a human recipient. Products regulated solely under Section 361 of the Public Health Service (PHS) Act are not required to undergo pre-market approval or investigational new drug (IND) application processes, provided they satisfy four strict statutory criteria:

Minimal Manipulation: Processing does not alter the relevant biological characteristics of structural tissue, or the cellular machinery of non-structural tissue.
Homologous Use: The product performs the same basic function in the recipient as in the donor.
No Combination: The tissue is not combined with another article, such as a drug or device, except for safe preservation agents.
Systemic Effect: The product does not depend on the metabolic activity of living cells for its primary function, or it is intended for autologous use, allogeneic use in first- or second-degree blood relatives, or reproductive use.

If a product fails to meet even one of these criteria, it is categorized as a Section 351 drug or biological product, requiring pre-market approval, clinical trial data, and licensing. Procurement officers must verify that all sourced [/biologics](biologics and allografts) comply strictly with Section 361 definitions.

The Section 361 Procurement Checklist for Compliance Officers

Practice managers and legal officers should apply this checklist to every tissue vendor, distributor, and processing facility prior to signing supply contracts or issuing purchase orders.

1. Vendor & Processing Facility Verification

[ ] FDA Establishment Registration: Verify that the manufacturing tissue bank holds an active FDA Establishment Registration (Form FDA 3356) and is currently listed on the FDA eLIST database.
[ ] State Tissue Bank Licensing: Confirm that the processor holds valid tissue bank licenses in all applicable states, including strict jurisdictions such as Texas, California, New York, and Florida.
[ ] Third-Party Accreditation: Check for active accreditation by recognized bodies such as the American Association of Tissue Banks (AATB).
[ ] Distributor Credentials: Confirm that intermediate distributors, such as [/about](Dallas Regenerative Solutions), maintain compliant storage facilities, state licenses, and documented quality management systems.

2. Product Classification & Technical Documentation

[ ] Minimal Manipulation Statement: Review technical files to ensure processing steps (e.g., micronization, cryopreservation, centrifugation) do not alter the inherent structural properties of the matrix.
[ ] Homologous Use Intended Design: Ensure the manufacturer’s product labeling and package insert state an intended use that aligns with homologous mechanical or structural support.
[ ] Certificate of Analysis (CoA): Require a lot-specific CoA for every batch, confirming sterility testing (USP <71>), endotoxin testing (USP <85>), and structural viability metrics where applicable.
[ ] Preservative & Additive Review: Verify that any added solution (such as DMSO or saline) is recognized as safe and non-toxic for the intended application method.

3. Donor Eligibility & Screening Protocols

[ ] Donor Screening Logs: Confirm compliance with 21 CFR 1271 Subpart C donor eligibility rules, including comprehensive medical history reviews and physical assessments.
[ ] Infectious Disease Panel: Verify negative test results for required communicable pathogens, including HIV-1/2, Hepatitis B (HBV), Hepatitis C (HCV), Syphilis, and Human T-Lymphotropic Virus (HTLV) where indicated.
[ ] CLIA-Certified Testing Facilities: Confirm that all donor screening laboratory assays were performed by CLIA-certified and FDA-registered laboratories.

4. Chain of Custody & Logistics Management

[ ] Temperature Controls: Ensure continuous cold-chain management during transit (e.g., dry ice, liquid nitrogen vapor phase, or 2–8°C control).
[ ] Temperature Indicators: Verify that shipments include validated, calibrated temperature monitoring devices or data loggers.
[ ] Lot Tracking Integration: Establish internal standard operating procedures (SOPs) to record tissue lot numbers, expiration dates, and patient medical record numbers (MRNs) for complete trace-back capability.

Clinical vs. Operational Vetting Considerations

Effective procurement requires balancing clinical utility with operational risk control. Both clinical leadership and practice management must evaluate products through their respective frameworks.

The Clinical Perspective: Structural Utility and Handling

Clinicians prioritize graft performance, structural integrity, and tissue preparation workflow within the procedure room. From a clinical standpoint, key evaluation metrics include:

Preparation Complexity: Evaluating reconstitution or thawing time required before delivery.
Viscosity and Handling: Assessing how the allograft passes through various needle gauges or delivery instruments without clogging.
Structural Functionality: Ensuring the allograft provides the necessary extracellular matrix scaffolding required for tissue support.

The Operational Perspective: Risk Exposure and Audit Readiness

Practice administrators and compliance officers focus on regulatory exposure, recordkeeping, and cost predictability. Key operational metrics include:

Regulatory Liability: Avoiding vendors that make unapproved systemic, disease-curing, or investigational biological claims on marketing materials.
Inventory Shelf Life: Balancing ambient, refrigerated, or cryogenic tissue storage capabilities against patient scheduling volume.
Supplier Stability: Partnering with established medical suppliers who provide transparent lot tracing, robust product liability coverage, and reliable inventory fulfillment.

Common Compliance Red Flags in Tissue Sourcing

Compliance officers must train procurement staff to identify red flags that indicate potential regulatory non-compliance:

Disease-Treatment Claims: Marketing literature claiming an HCT/P treats, cures, or mitigates systemic diseases (e.g., auto-immune conditions, neurodegenerative disorders, or systemic inflammation).
Exosome and Conditioned Media Marketing: Positioning extracellular vesicles, exosomes, or secretomes as unmanipulated Section 361 tissue products (the FDA explicitly classifies mass-isolated exosomes as Section 351 biological drugs requiring an IND).
Lack of Certificate of Analysis: Vendors unable to supply immediate, lot-specific sterility and donor screening documentation upon request.
Unregistered Intermediate Suppliers: Sourcing tissue through brokers or resellers who do not maintain temperature-controlled storage logs or proper distribution records.

What This Means for Your Practice

Implementing a robust procurement workflow reduces liability and elevates patient care standards. To update your practice protocol:

Conduct an Inventory Audit: Review all current allografts, structural matrices, and tissue products in your practice storage units against FDA establishment registration lists.
Establish Pre-Purchase Verification: Require vendors to complete your internal compliance questionnaire and provide CoAs before executing procurement agreements.
Update EMR Tracking Workflow: Standardize patient charts so that tissue lot numbers, donor ID codes, expiration dates, and clinical administration sites are recorded automatically.
Train Staff on Cold-Chain Acceptance: Train medical assistants and receiving staff to check transport temperature indicators before signing for delivered tissue shipments.

For assistance with clinical procurement, quality assurance documentation, or evaluating compliant tissue products, consult with the team at [/contact](Dallas Regenerative Solutions).